Abstract: The present invention provides methods of increasing bone mass in a human or other animal subject afflicted with osteoporosis, comprising a thirty(30)-day treatment period, comprised of a parathyroid hormone administration regimen and a bisphosphonate administration regimen, wherein(a) said parathyroid hormone administration regimen comprises the administration to said subject of parathyroid hormone at one or more level of from about 4 IU/kg per day to about 15 IU/kg per day that said parathyroid hormone is administered, provided that said parathyroid hormone is administered at least one day every seven days of every said thirty(30)-day treatment periods; and wherein(b) said bisphosphonate administration regimen comprises the administration to said subject of a bisphosphonate at a level of from about 0.0005 mgP/kg to about 1.0 mgP/kg per day that said bisphosphonate is administered, provided that said bisphosphonate is administered at least 1 day of every said thirty(30)-day treatment period.
Abstract: The present invention pertains to cyclosporin-containing liquid preparations for oral or parenteral administration, as well as to a process for preparing same. Besides the active ingredient cyclosporin, the preparations contain a polyoxyethylene glycerol fatty acid monoester and a monohydric and/or polyhydric alcohol(s). The preparations are stable and well tolerated, and they have higher bioavailability than the preparations known currently.
Abstract: A buffered intravesicular pharmaceutical dosage system for delivery of TGF.alpha.PE.sub.40 ab to a human bladder for bladder cancer chemotherapy, in which a buffer system of 100 mM phosphate at an initial pH of 7.8 maintains a pH range in the bladder of 6.5 to 7.8 that is sufficient to maximize interaction of TGF.alpha.PE.sub.40 ab with the EGF receptor expressed on the surface of bladder cancer cells and to prevent aggregation of the TGF.alpha.PE.sub.40 ab while in the bladder.
Type:
Grant
Filed:
June 27, 1996
Date of Patent:
March 18, 1997
Assignee:
Merck & Co., Inc.
Inventors:
Dorothy Marquis-Omer, C. Russell Middaugh, Gautam Sanyal
Abstract: The present invention includes methods and compositions for affecting the immune system in animals and humans. The methods and compositions include the administration of prolactin agonists to an immunosuppressed animal or human thereby stimulating the immune system. In addition, the present invention includes a vaccine adjuvant comprising the administration of a prolactin agonist with the vaccine.
Type:
Grant
Filed:
September 29, 1994
Date of Patent:
February 25, 1997
Assignee:
EntreMed, Inc.
Inventors:
Edward W. Bernton, John W. Holaday, Henry U. Bryant
Abstract: A method is provided for generation of bone at a site of an animal where skeletal tissue is deficient comprising administering to the animal, locally at the bone site in the presence of a source of osteogenic cells, an effective amount of a composition comprising TGF-.beta. in a pharmaceutically acceptable carrier, provided that such composition excludes a bone morphogenetic cofactor, the composition being administered in an amount effective to induce bone growth at the bone site. Also provided is a device for implantation into a site of an animal where skeletal tissue is deficient comprising a device treated with an effective amount of a composition comprising TGF-.beta. and a source of osteogenic cells in a pharmaceutically acceptable carrier.
Type:
Grant
Filed:
February 27, 1995
Date of Patent:
February 18, 1997
Assignee:
Genentech, Inc.
Inventors:
Arthur J. Ammann, Christopher G. Rudman
Abstract: A method is disclosed for treating obese mammals or preventing obesity from occurring in mammals. This method involves administering to the mammal an effective amount of growth hormone in combination with an effective amount of IGF-I. Preferably, the growth hormone is given so as to have a maintained, continual therapeutically effective presence in the blood, such as by continuous infusion or frequent injections, or by use of a long-acting formulation.
Abstract: The invention provides a method of treating a viral infection in a mammal comprising administering an effective amount of modified C-reactive protein (CRP) to the mammal. In particular, modified-CRP has been found to be effective and safe for treating retroviral infections, including human immunodeficiency virus 1. The invention also provides a method of neutralizing a virus comprising contacting the virus with modified-CRP. In particular, modified-CRP can be used to neutralize viruses in blood which is to be used for transfusions by adding the modified-CRP to the blood prior to the transfusion.
Abstract: This invention relates to a method of preventing hyperalgesia and other undesirable side-effects associated with the administration of growth factor, including nerve growth factor, utilizing an antagonist capable of inactivating excitatory opioid receptor-mediated functions on neurons in the nociceptive pathway. In addition, this invention relates to a composition comprising a growth factor and an antagonist capable of inactivating excitatory opioid receptor-mediated functions on neurons in the nociceptive pathway.
Type:
Grant
Filed:
August 13, 1993
Date of Patent:
December 17, 1996
Assignee:
Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva University
Inventors:
Stanley M. Crain, Ke-fei Shen, John A. Kessler, Stuart C. Apfel
Abstract: Tibial growth potentiating peptides which are unreactive in an enzyme immunoassay for human growth hormone have been isolated from human pituitary glands and human plasma. The peptides have a molecular weight of less than 10,000 daltons.
Type:
Grant
Filed:
October 12, 1994
Date of Patent:
November 19, 1996
Assignee:
The Penn State Research Foundation
Inventors:
Wesley C. Hymer, Krishnaswamy Krishnan, Wayne Lanham
Abstract: The present invention relates to the use of a pharmaceutic composition containing urodilatin as an active substance and optionally pharmaceutically usual diluents, excipients, fillers or adjuvants for treating pulmonary and/or bronchial diseases.
Abstract: A method is disclosed that comprises administering insulin-like growth factor-I (IGF-I) to a mammal so as to sustain its biological activity in the mammal comprising administering a therapeutically effective amount of IGF-I to the mammal to provide an exposure to IGF-I for a period of time that stimulates the maximum biological response in the mammal, then discontinuing said administration for a period of time equal to or less than the time period used for administration, and repeating this pattern of administration and discontinuance of administration for a period as long as necessary to achieve or maintain the desired biological response in the mammal.
Type:
Grant
Filed:
May 22, 1995
Date of Patent:
October 15, 1996
Assignees:
Genentech, Inc., Washington University
Inventors:
Ross G. Clark, Neil Gesundheit, Marc R. Hammerman, Steven B. Miller
Abstract: The invention relates to stabilized solutions with F VIII coagulation activity, to a process for the preparation thereof and to the use thereof.
Abstract: The invention concerns pharmaceutical compositions for use in the treatment of gastric disorders associated with Helicobacter pylori comprising a bacteriocin antimicrobial agent optionally coadministered with a release-delaying substance.
Abstract: An imidoester, cross-linked hemoglobin composition useful in the transport of oxygen to living cells and being essentially free of any impurities, a P50 of at least 13mm Hg and predominantly in tetraruer form. Preferably, the cross-linked hemoglobin composition has a predominant molecular weight of at least 64,000. The purified and cross-linked hemoglobin has improved cross-link stability to autoxidation and can be used as a blood substitute for mammals or as an oxygen transport fluid.
Type:
Grant
Filed:
June 15, 1994
Date of Patent:
May 28, 1996
Assignee:
The Upjohn Company
Inventors:
Robert L. Garlick, Joseph P. Martin, Jr., Stephen B. Lyle
Abstract: The invention relates, as new compounds, to derivatives of tetrameric human haemoglobin corresponding to the covalent coupling of a haemoglobin tetramer and a polycarboxy-substituted compound having at least 4 -COO.sup.- groups, the said polycarboxy-substituted compound effecting an internal crosslinking of the two dimers of haemoglobin and conferring thereon an affinity for oxygen which is compatible with an in vivo use of the conjugate when the natural allosteric effector of haemoglobin is not present. Among carboxy-substituted compounds, special mention is made of benzenehexacarboxylate and benzenetetracarboxylate.
Type:
Grant
Filed:
August 10, 1992
Date of Patent:
May 7, 1996
Assignee:
Pasteur Merieux Serums et Vaccins
Inventors:
Edith Dellacherie, Daniel Sacco, Michel Grandgeorge
Abstract: Administration of a corticotropin-releasing factor (or a salt or analog thereof) decreases the leakage of blood components into tissues produced by various adverse medical conditions. Thus, treatments with corticotropin-releasing factor are useful in systemic inflammatory conditions.
Type:
Grant
Filed:
April 19, 1994
Date of Patent:
January 30, 1996
Assignee:
The Regents of the University of California
Abstract: The present invention relates to the use of iGF-II or effective analogues thereof for the manufacture of a medicament for prevention or treatment of nutritional or gastrointestinal disorders and for promoting human or animal neonatal growth. It also relates to composition comprising exogenous human or animal IGF-II or effective analogues thereof in a therapeutically effective amount together with a pharmaceutically acceptable carrier or diluent or foodstuff, preferably in admixture with artificial or natural milk or colostrum. The invention may be applied both in man and in animals.
Abstract: This invention relates to new vasopressin and vasotocin derivatives of general formula I ##STR1## in which A stands for the radical Mca (=3-mercapto-3,3-cyclpentamethylenepropionyl radical) or for the radical Mpa (=3-mercaptopropionyl radical),B stands for the amino acid radicals D-Tyr, D-Tyr(Et), D-Phe, Tyr(OMe), D-lle, D-Trp, or the radical of a hydrophobic D-amino acid, andC stands for phenylalanine (Phe; vasopressin derivatives) or isoleucine (lle; vasotocin derivatives).They have a high activity toward the oxytocin and the V-vasopressin receptors and can be used for the production of pharmaceutical agents.
Type:
Grant
Filed:
December 20, 1993
Date of Patent:
November 28, 1995
Assignee:
Schering Aktiengesellschaft
Inventors:
Falk Fahrenholz, Walter Elger, Marianne Fahnrich, Kryzsztof Chwalisz